Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NRY4
UPID:
RHG35_HUMAN
Alternative names:
Glucocorticoid receptor DNA-binding factor 1; Glucocorticoid receptor repression factor 1; Rho GAP p190A
Alternative UPACC:
Q9NRY4; A7E2A4; Q14452; Q9C0E1
Background:
Rho GTPase-activating protein 35, known by its alternative names such as Glucocorticoid receptor DNA-binding factor 1 and Rho GAP p190A, plays a pivotal role in cellular processes. It acts as a Rho GTPase-activating protein (GAP), modulating the activity of Rho and Rac proteins. This protein is essential in cell differentiation, adhesion, migration, and various morphogenesis processes including retinal tissue, neural tube, and mammary gland development. It also transduces signals from p21-ras to the nucleus and regulates axon outgrowth and guidance.
Therapeutic significance:
Understanding the role of Rho GTPase-activating protein 35 could open doors to potential therapeutic strategies.